401 POSTER A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies
H.A. Wakelee, S.K. Padda, L. Chhatwani, M. San Pedro-Salcedo, Y. Krupitskaya, L. Musib, J.E. LatzVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72335-8
File:
PDF, 58 KB
english, 2008